Episode Details

In this episode from the series “Key Decisions in HIV Care,” W. David Hardy, MD, and Josep M. Llibre, MD, PhD, discuss important considerations for ART use in the context of virologic failure and resistance, including:

• A discussion of the definitions of the following: highly treatment experienced, complex ART, multidrug-resistant HIV, and limited treatment options
• The scope of the problem, including data from the CNICS cohort
• DHHS and EACS guideline recommendations on the management of virologic failure and drug resistance, including recommendations for the use of genotypic and phenotypic genotyping and proviral DNA sequencing
• Construction of an optimized background regimen with discussion of the OPTIONS, DAWNING, NADIA, and VIKING-3 trials
• Novel treatment options, including ibalizumab and data from TMB-301/-311, fostemsavir and data from BRIGHTE, and lenacapavir and data from CAPELLA

Presenters:

W. David Hardy, MD
Scientific and Medical Consultant
Adjunct Clinical Professor of Medicine
Division of Infectious Diseases
Keck School of Medicine of USC
Los Angeles, California

Josep M. Llibre, MD, PhD
S­enior Consultant Physician and Clinical Researcher
Infectious Disease and “Fight against AIDS and Infectious Diseases Foundation”
Hospital Universitari Germans Trias i Pujol
Badalona
Barcelona, Spain  

Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.

Follow along with the slides at: 
https://bit.ly/3z9AtL0

Link to full program:
https://bit.ly/2TXTYWx

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.